In the news

SomaLogic inks license deal with OncoHost to develop precision cancer diagnostics

Original source here

  • SomaLogic (NASDAQ:SLGC) on Monday said it had signed a licensing agreement with Israel-based OncoHost for the development of precision cancer diagnostics.
  • As per the agreement, OncoHost will license SLGC’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, which analyzes and monitors biological processes in a patient in response to a given cancer therapy.
  • As part of the deal, OncoHost will establish a lab in North Carolina where it will use the SomaScan Assay kits to run protein measurements on patient samples.

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
T. (855) 950-2112

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
T. +972 485 37558

Please Note:
PROphet® NSCLC is currently available in all US states except NY